Diabetes drug semaglutide may fight inflammation and protect blood vessels

NCT ID NCT07314684

Recruiting now Disease control Sponsor: Federico II University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 4 trial tests whether adding semaglutide to standard diabetes treatment reduces inflammation and improves blood vessel health in 80 people with type 2 diabetes who have no heart disease. Participants receive either semaglutide injections plus standard care or standard care alone for 52 weeks. Researchers will measure changes in inflammatory markers and blood vessel function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a GLP-1 receptor agonist drug)
What this could lead to: If successful, this could show that semaglutide helps control inflammation and blood vessel damage in type 2 diabetes, potentially reducing heart disease risk.
What could go wrong: This is a small, early-phase trial (80 people) looking at biomarkers, not clinical outcomes. The results may not translate to fewer heart attacks or strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T2DM (TYPE 2 DIABETES MELLITUS)

Contacts and locations

Locations

Azienda Ospedaliera Sant'Anna e San Sebastiano
RECRUITING

Caserta, Caserta, 81100, Italy
Federico II University
RECRUITING

Naples, Napoli, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.